Thomas Walther

List of Publications by Year
in descending order

70 papers	4,449 citations	159585 30 h-index	102487 66 g-index
70 all docs	70 docs citations	70 times ranked	4834 citing authors

#	Article	IF	Citations
1	Treatment with Angiotensin-(1-7) Prevents Development of Oral Papilloma Induced in K-ras Transgenic Mice. International Journal of Molecular Sciences, 2022, 23, 3642.	4.1	1
2	Oestrogen-mediated upregulation of the Mas receptor contributes to sex differences in acute lung injury and lung vascular barrier regulation. European Respiratory Journal, 2021, 57, 2000921.	6.7	28
3	ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinoma. Science Translational Medicine, 2021, 13, .	12.4	29
4	Measurement of multiple cytokines for discrimination and risk stratification in patients with Chagasâ€™ disease and idiopathic dilated cardiomyopathy. PLoS Neglected Tropical Diseases, 2021, 15, e0008906.	3.0	4
5	Angiotensin-(1-7)â€"A Potential Remedy for AKI: Insights Derived from the COVID-19 Pandemic. Journal of Clinical Medicine, 2021, 10, 1200.	2.4	18
6	Combining VEGF receptor inhibitors and angiotensin-(1â€“7) to target renal cell carcinoma. Molecular and Cellular Oncology, 2021, 8, 1918529.	0.7	2
7	Localization and expression of the Mas-related G-protein coupled receptor member D (MrgD) in the mouse brain. Heliyon, 2021, 7, e08440.	3.2	4
8	The virtually mature Bâ€type natriuretic peptide (BNP1â€32) is a precursor for the more effective BNP1â€30. British Journal of Pharmacology, 2020, 177, 1424-1433.	5.4	2
9	Donâ€™t judge too RAShly: the multifaceted role of the renin-angiotensin system and its therapeutic potential in COVID-19. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 318, L1023-L1024.	2.9	6
10	Short-Term Western Diet Aggravates Non-Alcoholic Fatty Liver Disease (NAFLD) With Portal Hypertension in TGR(mREN2)27 Rats. International Journal of Molecular Sciences, 2020, 21, 3308.	4.1	7
11	TGR(mREN2)27 rats develop non-alcoholic fatty liver disease-associated portal hypertension responsive to modulations of Janus-kinase 2 and Mas receptor. Scientific Reports, 2019, 9, 11598.	3.3	10
12	Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. European Heart Journal, 2018, 39, 2274-2281.	2.2	16
13	Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 180-188.	3.0	113
14	Decarboxylation of Ang-(1â€“7) to Ala1-Ang-(1â€“7) leads to significant changes in pharmacodynamics. European Journal of Pharmacology, 2018, 833, 116-123.	3.5	23
15	Neprilysin degrades murine Amyloid-Î² (AÎ²): Further implication for species-specific amyloid accumulation. Neuroscience Letters, 2018, 686, 74-79.	2.1	9
16	Further intracellular proteins and signaling pathways regulated by angiotensin-(1â€“7) in human endothelial cells. Data in Brief, 2017, 10, 354-363.	1.0	2
17	Comprehensive efforts to increase adherence to statin therapy. European Heart Journal, 2017, 38, ehw628.	2.2	40
18	Mas receptor is involved in the estrogen-receptor induced nitric oxide-dependent vasorelaxation. Biochemical Pharmacology, 2017, 129, 67-72.	4.4	34

#	Article	IF	Citations
19	Angiotensin-(1-7) counteracts the transforming effects triggered by angiotensin II in breast cancer cells. Oncotarget, 2017, 8, 88475-88487.	1.8	26
20	Role of Monokine Induced by Interferon Gamma in Discrimination and Prognosis of Patients With Chagas' Disease and Idiopathic Dilated Cardiomyopathy. Journal of Cardiovascular Pharmacology, 2016, 67, 427-432.	1.9	3
21	Rare Variants in MME, Encoding Metalloprotease Neprilysin, Are Linked to Late-Onset Autosomal-Dominant Axonal Polyneuropathies. American Journal of Human Genetics, 2016, 99, 607-623.	6.2	47
22	The Angiotensin-(1â€“7)/Mas Axis Improves Pancreatic Î²-Cell Function in Vitro and in Vivo. Endocrinology, 2016, 157, 4677-4690.	2.8	35
23	The High Blood Pressure-Malaria Protection Hypothesis. Circulation Research, 2016, 119, 1071-1075.	4.5	31
24	G-Proteinâ€“Coupled Receptor MrgD Is a Receptor for Angiotensin-(1â€“7) Involving Adenylyl Cyclase, cAMP, and Phosphokinase A. Hypertension, 2016, 68, 185-194.	2.7	109
25	Therapeutic time window for angiotensinâ€(1â€“7) in acute lung injury. British Journal of Pharmacology, 2016, 173, 1618-1628.	5.4	28
26	Identification of intracellular proteins and signaling pathways in human endothelial cells regulated by angiotensin-(1â€“7). Journal of Proteomics, 2016, 130, 129-139.	2.4	11
27	Angiotensin receptors and Î²-catenin regulate brain endothelial integrity in malaria. Journal of Clinical Investigation, 2016, 126, 4016-4029.	8.2	52
28	Doseâ€Dependent, Therapeutic Potential of Angiotensinâ€(1â€“7) for the Treatment of Pulmonary Arterial Hypertension. Pulmonary Circulation, 2015, 5, 649-657.	1.7	28
29	Multiple non-coding exons and alternative splicing in the mouse Mas protooncogene. Gene, 2015, 568, 155-164.	2.2	1
30	Beta Blockers Prevent Correlation of Plasma ACE2 Activity With Echocardiographic Parameters in Patients With Idiopathic Dilated Cardiomyopathy. Journal of Cardiovascular Pharmacology, 2015, 65, 8-12.	1.9	5
31	Hemodynamic Effects of the Non-Peptidic Angiotensin-(1-7) Agonist AVE0991 in Liver Cirrhosis. PLoS ONE, 2015, 10, e0138732.	2.5	29
32	Cardiovascular variability before and after delivery: recovery from arterial stiffness in women with preeclampsia 4â€‰days post partum. Hypertension in Pregnancy, 2014, 33, 1-14.	1.1	10
33	Prognostic value of circulating levels of stem cell growth factor beta (SCGF beta) in patients with Chagasâ€™ disease and idiopathic dilated cardiomyopathy. Cytokine, 2013, 61, 728-731.	3.2	16
34	Chimeric natriuretic peptide ACNP stimulates both natriuretic peptide receptors, the NPRA and NPRB. Molecular and Cellular Endocrinology, 2013, 366, 117-123.	3.2	5
35	Complete blockade of the vasorelaxant effects of angiotensinâ€(1â€“7) and bradykinin in murine microvessels by antagonists of the receptor Mas. Journal of Physiology, 2013, 591, 2275-2285.	2.9	28
36	Angiotensin-(1â€“7) Protects From Experimental Acute Lung Injury. Critical Care Medicine, 2013, 41, e334-e343.	0.9	101

#	Article	IF	Citations
37	Prognostic Significance of Circulating Levels of Hepatocyte Growth Factor in Patients with Chagasâ€™ Disease and Idiopathic Dilated Cardiomyopathy. Cardiology, 2012, 121, 240-246.	1.4	7
38	Does the Aminopeptidase A Have Prognostic and Diagnostic Value in Chagas Disease and Other Dilated Cardiomyopathies?. Journal of Cardiovascular Pharmacology, 2011, 58, 374-379.	1.9	5
39	Pressor and Renal Hemodynamic Effects of the Novel Angiotensin A Peptide Are Angiotensin II Type 1A Receptor Dependent. Hypertension, 2011, 57, 956-964.	2.7	42
40	Renal vasoconstrictor and pressor responses to angiotensin IV in mice are AT1a-receptor mediated. Journal of Hypertension, 2010, 28, 487-494.	0.5	32
41	Circulating Rather Than Cardiac Angiotensin-(1-7) Stimulates Cardioprotection After Myocardial Infarction. Circulation: Heart Failure, 2010, 3, 286-293.	3.9	77
42	Plasma ACE2 Activity is an Independent Prognostic Marker in Chagas' Disease and Equally Potent as BNP. Journal of Cardiac Failure, 2010, 16, 157-163.	1.7	45
43	Improved Learning and Memory in Aged Mice Deficient in Amyloid Î²-Degrading Neutral Endopeptidase. PLoS ONE, 2009, 4, e4590.	2.5	30
44	Angiotensin-(1â€“7) and the G Protein-Coupled Receptor Mas Are Key Players in Renal Inflammation. PLoS ONE, 2009, 4, e5406.	2.5	117
45	Structural Substrate Conditions Required for Neutral Endopeptidase-Mediated Natriuretic Peptide Degradation. Journal of Molecular Biology, 2009, 393, 496-503.	4.2	43
46	Impaired spatial memory and altered dendritic spine morphology in angiotensin II type 2 receptor-deficient mice. Journal of Molecular Medicine, 2008, 86, 563-571.	3.9	49
47	Catabolic attacks of membrane-bound angiotensin-converting enzyme on the N-terminal part of species-specific amyloid-Î² peptides. European Journal of Pharmacology, 2008, 588, 18-25.	3.5	35
48	Prognostic Value of Natriuretic Peptides in Chagasâ€™ Disease: A 3-Year Follow-Up Investigation. Cardiology, 2008, 110, 217-225.	1.4	23
49	Human Minimally Invasive Off-Pump Valve-in-a-Valve Implantation. Annals of Thoracic Surgery, 2008, 85, 1072-1073.	1.3	109
50	Angiotensin(1-7) Blunts Hypertensive Cardiac Remodeling by a Direct Effect on the Heart. Circulation Research, 2008, 103, 1319-1326.	4.5	206
51	Hemodynamic Assessment Using Apical Suction versus Pericardial Retraction in Beating Heart Surgery. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2008, 3, 125-130.	0.9	0
52	Successive Action of Meprin A and Neprilysin Catabolizes B-Type Natriuretic Peptide. Circulation Research, 2007, 101, 875-882.	4.5	72
53	Endothelial dysfunction through genetic deletion or inhibition of the G protein-coupled receptor Mas: a new target to improve endothelial function. Journal of Hypertension, 2007, 25, 2421-2425.	0.5	74
54	Reverse remodeling of cardiac collagen protein expression after surgical therapy for experimental aortic stenosis. Journal of Heart Valve Disease, 2006, 15, 651-6.	0.5	5

#	Article	IF	Citations
55	G-Proteinâ€“Coupled Receptor Mas Is a Physiological Antagonist of the Angiotensin II Type 1 Receptor. Circulation, 2005, 111, 1806-1813.	1.6	346
56	Biochemical analysis of neutral endopeptidase activity reveals independent catabolism of atrial and brain natriuretic peptide. Biological Chemistry, 2004, 385, 179-84.	2.5	26
57	Relation of ANP and BNP to their N-terminal fragments in fetal circulation: evidence for enhanced neutral endopeptidase activity and resistance of BNP to neutral endopeptidase in the fetus. BJOG: an International Journal of Obstetrics and Gynaecology, 2004, 111, 452-455.	2.3	23
58	Fibrosis rather than blood pressure determines cardiac BNP expression in mice. Regulatory Peptides, 2003, 116, 95-100.	1.9	26
59	Angiotensin-(1â€“7) is an endogenous ligand for the G protein-coupled receptor Mas. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 8258-8263.	7.1	1,555
60	Differential regulation of in vivo angiogenesis by angiotensin II receptors. FASEB Journal, 2003, 17, 2061-2067.	0.5	110
61	Angiotensin II and the Amygdala. Annals of the New York Academy of Sciences, 2003, 985, 498-500.	3.8	4
62	AT1 receptor blockade increases cardiac bradykinin via neutral endopeptidase after induction of myocardial infarction in rats. FASEB Journal, 2002, 16, 1237-1241.	0.5	23
63	Cell Type-specific Expression of the Mas Proto-oncogene in Testis. Journal of Histochemistry and Cytochemistry, 2002, 50, 691-695.	2.5	37
64	Natriuretic peptide system in fetal heart and circulation. Journal of Hypertension, 2002, 20, 785-791.	0.5	31
65	Imprinting of the Murine Mas Protooncogene Is Restricted to Its Antisense RNA. Biochemical and Biophysical Research Communications, 2002, 290, 1072-1078.	2.1	18
66	Fetal, neonatal cord, and maternal plasma concentrations of angiotensin-converting enzyme (ACE). Prenatal Diagnosis, 2002, 22, 111-113.	2.3	14
67	Upregulation of bradykinin B1-receptor expression after myocardial infarction. British Journal of Pharmacology, 2000, 129, 1537-1538.	5.4	57
68	Interaction Between Mas and the Angiotensin AT1 Receptor in the Amygdala. Journal of Neurophysiology, 2000, 83, 2012-2021.	1.8	70
69	Sex specific behavioural alterations in Mas-deficient mice. Behavioural Brain Research, 2000, 107, 105-109.	2.2	40
70	Sustained Long Term Potentiation and Anxiety in Mice Lacking theMas Protooncogene. Journal of Biological Chemistry, 1998, 273, 11867-11873.	3.4	185